oncnursingnews1d
Enhancing Early-Stage NSCLC Care: Streamlining Biomarker Testing and Multidisciplinary Coordination Through Quality Improvement Initiatives
Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure ...
oncnursingnews3d
How to Overcome 4 Common Barriers to Cancer Clinical Trial Access
An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and ...
oncnursingnews5d
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
oncnursingnews6d
Kathryn Ciccolini
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews6d
Letter Warns Clinicians of Severe Infections With Pralsetinib for NSCLC
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...
oncnursingnews7d
Barbara A. Leone, RN, BSN, CCM
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews7d
Kathryn Canavan
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews7d
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma
An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma. Ciltacabtagene autoleucel (cilta-cel; Carvykti) ...
oncnursingnews8d
Jennifer L. Redmond, DrPH
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews8d
Mabel Ryder, MD
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...